Back to Journals » Drug, Healthcare and Patient Safety » Volume 6

Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study

Authors Denholm J, McBryde E, Eisen D, Penington J, Chen C, Street A

Received 4 June 2014

Accepted for publication 8 July 2014

Published 21 October 2014 Volume 2014:6 Pages 145—149

DOI https://doi.org/10.2147/DHPS.S68837

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Justin T Denholm,1,4,5 Emma S McBryde,1,3 Damon P Eisen,1,3 Jocelyn S Penington,1 Caroline Chen,2 Alan C Street1

1Victorian Infectious Diseases Service, 2Department of Pharmacy, Royal Melbourne Hospital, Parkville, Vic, Australia; 3Department of Medicine (RMH/WH), 4Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic, Australia; 5Victorian Tuberculosis Program, Melbourne Health, Parkville, Vic, Australia


Introduction: Isoniazid preventative therapy (IPT) is a widely used intervention for treatment of latent tuberculosis infection (LTBI), particularly in patients at high risk for reactivation. While treatment-limiting adverse effects have been well studied, few prospective studies have considered the range of adverse effects that patients may experience with IPT.
Methods: All patients commencing treatment for LTBI were prospectively enrolled in an ongoing database of LTBI treatment outcomes particularly related to adverse effects, treatment adherence, and treatment completion.
Results: Data on the first 100 patients who were prescribed IPT are presented. Fifty-six patients reported at least one adverse effect at some stage during treatment, with six experiencing at least one World Health Organization (WHO) Grade 3–4 adverse effect. Increased age was significantly associated with risk of adverse effects (odds ratio [OR] =1.05 per year; confidence interval [CI] of 1.02–1.08=95%). Eighty-five patients had documented completion of therapy locally, with ten patients ceasing IPT due to adverse effects.
Discussion: This report highlights a variety of somatic adverse effects that occurred in a real-world cohort of patients receiving IPT. While adverse effects were frequently identified in this study, the considerable majority were low grade and transient. Despite frequent adverse effects of LTBI in our treatment cohort, the study demonstrated high levels of treatment adherence and completion.

Keywords: latent tuberculosis infection, isoniazid preventative therapy, treatment toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]